Takeda Pharmaceutical (NYSE:TAK) Insider Lauren Rusckowski Duprey Sells 34,535 Shares of Stock

Takeda Pharmaceutical Co. (NYSE:TAK) insider Lauren Duprey sold 34,535 shares of the company’s stock in a transaction on Monday, September 14th. The shares were sold at an average price of $18.54, for a total value of $640,278.90. Following the completion of the transaction, the insider directly owned 191,522 shares in the company, valued at $3,550,817.88. This represents a 15.28% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Lauren Rusckowski Duprey also recently made the following trade(s):

• On Monday, August 10th, Lauren Duprey sold 47,586 shares of Takeda Pharmaceutical stock. The stock was sold at an average price of $17.10, for a total value of $813,720.60.

Takeda Pharmaceutical Price Performance

Shares of NYSE TAK traded up $0.11 during mid-day trading on Tuesday, reaching $18.71. The company had a trading volume of 2,678,363 shares, compared to its average volume of 2,044,457. The company has a 50-day moving average price of $17.58 and a two-hundred day moving average price of $17.19. The stock has a market cap of $59.95 billion, a PE ratio of 55.03 and a beta of -0.07. The company has a current ratio of 1.14, a quick ratio of 0.62 and a debt-to-equity ratio of 0.58. Takeda Pharmaceutical Co. has a 1-year low of $12.99 and a 1-year high of $18.90.

Takeda Pharmaceutical (NYSE:TAK) last announced its earnings results on Thursday, July 30th. The company reported $0.95 EPS for the quarter, beating the consensus estimate of $0.41 by $0.54. Takeda Pharmaceutical had a return on equity of 10.95% and a net margin of 3.80%.The business had revenue of $7.50 billion during the quarter, compared to the consensus estimate of $7.13 billion. Takeda Pharmaceutical has set its FY 2026 guidance at 3.009-3.009 EPS. On average, equities analysts anticipate that Takeda Pharmaceutical Co. will post 1.54 earnings per share for the current year.

Analyst Ratings Changes

TAK has been the subject of a number of analyst reports. Zacks Research raised shares of Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, September 2nd. Wall Street Zen raised shares of Takeda Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Finally, Weiss Ratings upgraded shares of Takeda Pharmaceutical from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy”.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. SHP Wealth Management bought a new stake in shares of Takeda Pharmaceutical in the 4th quarter valued at approximately $42,000. Manchester Capital Management LLC raised its holdings in Takeda Pharmaceutical by 91.4% during the fourth quarter. Manchester Capital Management LLC now owns 4,649 shares of the company’s stock valued at $72,000 after buying an additional 2,220 shares in the last quarter. Harbour Investments Inc. raised its holdings in Takeda Pharmaceutical by 300.3% during the fourth quarter. Harbour Investments Inc. now owns 4,612 shares of the company’s stock valued at $72,000 after buying an additional 3,460 shares in the last quarter. Rockefeller Capital Management L.P. lifted its position in shares of Takeda Pharmaceutical by 30.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 5,184 shares of the company’s stock worth $81,000 after buying an additional 1,215 shares during the last quarter. Finally, TD Private Client Wealth LLC boosted its stake in shares of Takeda Pharmaceutical by 3,783.0% during the 4th quarter. TD Private Client Wealth LLC now owns 9,824 shares of the company’s stock worth $153,000 after acquiring an additional 9,571 shares in the last quarter. Institutional investors and hedge funds own 9.17% of the company’s stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited is a global biopharmaceutical company headquartered in Japan. The company researches, develops, manufactures and markets prescription medicines and vaccines for patients and healthcare professionals around the world.

Takeda focuses on several therapeutic areas, including gastrointestinal and inflammatory diseases, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Its portfolio includes treatments such as Entyvio for inflammatory bowel disease, Takhzyro for hereditary angioedema, Ninlaro for multiple myeloma and Iclusig for certain blood cancers, along with other specialty medicines and vaccines.

Founded in Osaka in 1781, Takeda has grown from a traditional pharmaceutical distributor into an international biopharmaceutical company serving markets across Japan, North America, Europe and other regions.